A Kaletra ONCE daily randomized trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily Lopinavir/Ritonavir tablets dosed by weight as part of combination antiretroviral therapy in HIV-1 infected children

This study will evaluate once daily lopinavir/ritonavir-based HAART in virological suppressed children.

Publication: Pediatr Infect Dis J. 2014;33(3):301-5.

Presentations:

1. Kaletra (ALUVIA) ONCE daily Randomised Trial of PK, safety & efficacy of QD v BID lopinavir/ritonavir tablets (PENTA 18) at CROI
2. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 4^th International Workshop on HIV Pediatrics at July 20-21, 2012 at Washington DC, USA